Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

Fredrik H Schjesvold; Heinz Ludwig; Sossana Delimpasi; Pawel Robak; Daniel Coriu; Waldemar Tomczak; Ludek Pour; Ivan Spicka; Meletios-Athanasios Dimopoulos; Tamas Masszi; Natalia G Chernova; Anna Sandberg; Marcus Thuresson; Stefan Norin; Nicolaas A Bakker; Maria-Victoria Mateos; Paul G Richardson; Pieter Sonneveld

doi:10.3324/haematol.2023.284635

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

Haematologica. 2024 Jul 1;109(7):2331-2336. doi: 10.3324/haematol.2023.284635.

Authors

Fredrik H Schjesvold¹, Heinz Ludwig², Sossana Delimpasi³, Pawel Robak⁴, Daniel Coriu⁵, Waldemar Tomczak⁶, Ludek Pour⁷, Ivan Spicka⁸, Meletios-Athanasios Dimopoulos⁹, Tamas Masszi¹⁰, Natalia G Chernova¹¹, Anna Sandberg¹², Marcus Thuresson¹², Stefan Norin¹², Nicolaas A Bakker¹², Maria-Victoria Mateos¹³, Paul G Richardson¹⁴, Pieter Sonneveld¹⁵

Affiliations

¹ Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. fredrikschjesvold@gmail.com.
² Department of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna.
³ Bone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece.
⁴ Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
⁵ University of Medicine and Pharmacy "Carol Davila", Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
⁶ Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin.
⁷ Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
⁸ 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic.
⁹ Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
¹⁰ Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
¹¹ National Research Center for Haematology, Moscow, Russia.
¹² Oncopeptides AB, Stockholm, Sweden.
¹³ Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain.
¹⁴ Dana-Farber Cancer Institute, Boston, MA.
¹⁵ Erasmus MC Cancer Institute, Rotterdam.

No abstract available

Publication types

Clinical Trial, Phase III
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Dexamethasone* / administration & dosage
Dexamethasone* / therapeutic use
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Phenylalanine / analogs & derivatives
Phenylalanine / therapeutic use
Quality of Life*
Recurrence
Treatment Outcome

Substances

Dexamethasone
Phenylalanine

Associated data

ClinicalTrials.gov/NCT03151811

Grants and funding

Funding: Funding for the study (ClinicalTrials.gov identifier: NCT03151811) and for editorial assistance was provided by Oncopeptides AB.